Home › Metastatic Cancer › NCT05010031
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RecruitingPhase 2
Phase II Study to Examine Precision Radiation in Patients With Pathogenic Mutations in ATM
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Histologically confirmed malignancy with at least one metastatic lesion referred for palliative radiotherapy * Pathogenic mutation in ATM (somatic and germline allowed) * ECOG performance status 0-2 * Age ≥ 18 years. * Able to provide informed consent. * Patients at reproductive potential must agree to practice an effective contraceptive method during radiation treatments. * Expected life expectancy of at least 6 months Exclusion Criteria: * Previous radiotherapy to the intended treatment site that precludes developing a treatment plan that respects normal tissue tolerances. * Serious medical co-morbidities precluding radiotherapy. * Pregnant or breast-feeding women. * Lesions excluded from de-escalation include regions in which the risk of local disease progression is unacceptably high, including CNS disease and cord compression, and areas in which re-irradiation would not be feasible, including spinal cord overlap.
About the study
This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would still be effective to treat these tumors.
What is being tested
- Palliative radiotherapy (radiation)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 45 · Started: Aug 11, 2021
Contact the study team
- Amy Xu, MD, PhD · Phone: 646-888-6863
- Daniel Gomez, MD · Phone: 212-639-2087
Official record on ClinicalTrials.gov — NCT05010031
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.